Market Scenario:
The adrenal glands within the
body produce some essential hormones like aldosterone. This hormone balances
the levels of sodium and potassium in the blood. Primary aldosteronism is a
medical condition in which the adrenal glands produce high levels of aldosterone,
causing the patient to lose potassium and retain sodium. This excess levels of
sodium, increases the blood volume and blood pressure. The diagnosis and
treatment of primary aldosteronism is important because it increases the risk
of the heart diseases and stroke. This has provided the essential background
for market growth. Factors such as increasing prevalence of primary
aldosteronism and the growing geriatric population are the major drivers for
the market growth. According to a study published in the International Journal
of Endocrinology and Metabolism in 2016, the prevalence of the primary
aldosteronism was estimated to be greater than 5%. Moreover, increasing obese
population and rising consumption of alcohol is estimated to fuel the market. According
to the World Health Organization, in 2016, approximately 1.9 billion adults
aged 18 years or more were overweight. Moreover, it was estimated that out this
population more than 650 million were obese. Additionally, rising per capita
healthcare expenditure boosts the market growth. However, lack of awareness and
risks associated with corrective surgeries like excessive bleeding, infection,
anesthesia reaction besides others are estimated to restrain the market growth
during the forecast period.
The global primary aldosteronism
market is expected to grow at a CAGR of 8.40% during forecast period.
Intended Audience
- Pharmaceutical companies
- Biotechnological institutes
- Government and Private
Laboratories
- Research and Development
(R&D) Companies
- Medical Research
Laboratories
- Market Research and
Consulting Service Providers
Segmentation
The global primary aldosteronism
market is segmented on the basis of type, indications, diagnosis, treatment and
end users.
On the basis of type, the market
is segmented as Type I, and Type II. On the basis of indications, the market is
categorized into heart attack, kidney failure, stroke, and others. On the basis
of diagnosis, the market is segmented into blood test, imaging, and others. The
blood test segment is sub-segmented into aldosterone profiling, renin
profiling, and others. The imaging segment is sub-segmented into computed
tomography (CT), positron emission tomography (PET), and others.On the basis of
end users, the market is segmented into surgery, aldosterone antagonists, and
others. The aldosterone antagonists is sub-m segmented into spironolactone,
eplerenone, and others.
Regional Analysis
America dominates the global
primary aldosteronism market owing to a well-developed healthcare sector and a
huge patient population. Apart from this, changing lifestyle and increasing
healthcare expenditure have boosted the growth of the market in America.
According to the Population Reference Bureau, the American geriatric population
is projected to double and reach approximately over 98 million by 2060.
Europe is the second largest
market for primary aldosteronism, and is followed by Asia Pacific. Availability
of funds for research, a huge patient population and government support for
research & development are the driving factors for the market within the
region. On a regional basis, the market is segmented into Western Europe, and
Eastern Europe. The Western Europe leads the market due to the presence of
developed economies like Germany, Italy, France, and others. On the other hand,
Eastern Europe is estimated to be the fastest growing market.
Asia Pacific is projected to be
the fastest growing region for the market due to the presence of a huge patient
population, continuously developing economies like India and China. According
to the Indian Brand Equity Foundation, the Indian healthcare sector is
estimated to be one of the fastest growing sectors and is projected to advance
at an estimated CAGR of 22.87% from 2015 to 2020 and reach USD 280 billion till
2020.
On the other hand, the Middle
East & Africa has the least share in the global primary aldosteronism
market due to the presence of weak economies, stringent government policies and
lack of healthcare services especially within the African region. A majority of
the market within the Middle East and Africa is held by the Middle East due to
a well-developed healthcare sector and huge healthcare expenditure in the
region.
Request Full
Report @ https://www.marketresearchfuture.com/reports/primary-aldosteronism-market-5522
Key players for global primary
Aldosteronism market
The key players for the global
primary aldosteronism market are Pfizer Inc. (U.S.), Sun Pharmaceutical
Industries Ltd. (India), Bristol Laboratories Ltd (England), CMP Pharma.
(U.S.), Koninklijke Philips N.V. (The Netherlands), GE Healthcare (U.K),
Siemens AG (Germany), Shimadzu Corporation (Japan), Canon Inc. (Japan), and
others.
About
US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312l
Email:
sales@marketresearchfuture.com
